Gemcitabine

Generic Name
Gemcitabine
Brand Names
Gemzar
Drug Type
Small Molecule
Chemical Formula
C9H11F2N3O4
CAS Number
95058-81-4
Unique Ingredient Identifier
B76N6SBZ8R
Background

Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication

Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions
Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer

Phase 2
Completed
Conditions
Breast Cancer
First Posted Date
2005-09-19
Last Posted Date
2007-08-31
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
80
Registration Number
NCT00192062
Locations
🇪🇬

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Giza, Egypt

Study of Gemcitabine and Concurrent Radiation Followed by Adjuvant Hysterectomy in Bulky Stage Ib and IIa Cervical Carcinoma

Phase 1
Completed
Conditions
Uterine Cervical Cancer
Interventions
Drug: Gemcitabine
First Posted Date
2005-09-16
Last Posted Date
2017-08-15
Lead Sponsor
University of Southern California
Target Recruit Count
35
Registration Number
NCT00184093
Locations
🇺🇸

USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

A Phase I/II Study of Lenalidomide in Combination With Gemcitabine in Patients With Untreated Advanced Carcinoma of the Pancreas

Phase 1
Terminated
Conditions
Pancreatic Cancer
First Posted Date
2005-09-16
Last Posted Date
2005-11-07
Lead Sponsor
Celgene Corporation
Target Recruit Count
50
Registration Number
NCT00179751
Locations
🇺🇸

Sarah Cannon Cancer Center, Nashville, Tennessee, United States

🇺🇸

Cancer and Blood Institute, Metairie, Louisiana, United States

🇺🇸

Charleston Cancer Center, Charleston, South Carolina, United States

and more 3 locations

Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer

Phase 1
Completed
Conditions
Pancreatic Cancer
Interventions
Drug: Vatalanib
Drug: Gemcitabine
First Posted Date
2005-09-16
Last Posted Date
2014-09-15
Lead Sponsor
George Albert Fisher
Target Recruit Count
33
Registration Number
NCT00185588
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Phase I Trial of Biweekly Gemcitabine & Paclitaxel & Low-Dose Radiation for Metastatic or Recurrent Head & Neck Cancer

First Posted Date
2005-09-15
Last Posted Date
2015-06-08
Lead Sponsor
Susanne Arnold
Target Recruit Count
7
Registration Number
NCT00176241
Locations
🇺🇸

University of Kentucky, Lexington, Kentucky, United States

Study of Metastatic Ocular Melanoma

Phase 2
Conditions
Ocular Melanoma
First Posted Date
2005-09-15
Last Posted Date
2007-08-31
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
48
Registration Number
NCT00168870
Locations
🇩🇪

Hematology & Oncology Charité CBF Berlin, Berlin, Germany

Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer

Phase 2
Completed
Conditions
Pancreatic Cancer
First Posted Date
2005-09-15
Last Posted Date
2008-05-06
Lead Sponsor
University of Michigan Rogel Cancer Center
Target Recruit Count
5
Registration Number
NCT00176813
Locations
🇺🇸

University of Michigan, Ann Arbor, Michigan, United States

Phase I/II Trial GOFL in Advanced Pancreatic Adenocarcinoma

Phase 1
Completed
Conditions
Pancreatic Adenocarcinoma
First Posted Date
2005-09-12
Last Posted Date
2005-09-12
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
45
Registration Number
NCT00154791
Locations
🇨🇳

National Taiwan Univeristy Hospital, Taipei, Taiwan

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

Phase 2
Completed
Conditions
Non-Small Cell Lung Cancer
First Posted Date
2005-09-12
Last Posted Date
2008-08-04
Lead Sponsor
National Taiwan University Hospital
Target Recruit Count
86
Registration Number
NCT00154739
Locations
🇨🇳

Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan

Study of Carboplatin/Gemcitabine Plus Bevacizumab in Advanced Lung Cancer

First Posted Date
2005-09-08
Last Posted Date
2005-11-29
Lead Sponsor
St. John Providence Health System
Target Recruit Count
45
Registration Number
NCT00150657
Locations
🇺🇸

Providence Cancer Institute, Southfield, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy